ASCO 2021 Highlights From IMpower 010 on Resected Stage IB-IIIA NSCLC: Atezolizumab vs. BSC After Adjuvant Chemotherapy

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ASCO 2021 Highlights From IMpower 010 on Resected Stage IB-IIIA NSCLC: Atezolizumab vs. BSC After Adjuvant Chemotherapy

By City of Hope FEATURING Jack West

573 views

July 1, 2021

This video was recorded prior to the FDA granting approval to Atezolizumab on 10/15/2021 as ...
read more ↘ adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC
↖ read less

0 Comments

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams